Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.69 USD | -5.34% | +0.41% | -15.46% |
02:03pm | Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 | MT |
Apr. 30 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.46% | 1.44B | |
+3.88% | 108B | |
+11.07% | 104B | |
+1.28% | 22.33B | |
-12.91% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.22% | 17.64B | |
+3.60% | 14.05B | |
+37.02% | 12.51B |
- Stock Market
- Equities
- AKRO Stock
- News Akero Therapeutics, Inc.
- Akero Therapeutics' Shares Gain Nearly 5% After Reporting Narrower Q2 Loss; Efruxifermin in Phase 2 Clinical Development